Intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a cost‐effectiveness analysis

In a Dutch national study, we recently established the effectiveness and safety of continuous intrathecal baclofen infusion (CITB) in children with intractable spastic cerebral palsy (CP). Because prospective studies on the cost‐effectiveness of CITB in children with spastic CP are lacking, we conducted a cost‐effectiveness analysis alongside our prospective national study. We compared the costs and health effects of CITB with those of standard treatment only, from the health care perspective for a 1‐year period. Health effects were expressed in terms of a visual analogue scale for individual problems and quality‐adjusted life years (QALYs). We included eight females and seven males, aged between 7 and 17 years (mean age 13y 8mo [SD 3y]). Eleven children had spastic CP and four had spastic‐dyskinetic CP. One child was clsssified on the Gross Motor Function Classification System at Level III, two at Level IV, and 12 at Level V. CITB was more effective and more costly than standard treatment only. Gaining one QALY cost on average €32 737. We conclude that based on the threshold‐willingness to pay for one QALY in the Netherlands (€80 000), our results confirm the cost‐effectiveness of CITB for carefully selected children with intractable spastic CP.